News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
734,893 Results
Type
Article (41604)
Company Profile (231)
Press Release (693047)
Multimedia
Podcasts (97)
Webinars (21)
Section
Business (204961)
Career Advice (2036)
Deals (35639)
Drug Delivery (134)
Drug Development (81654)
Employer Resources (173)
FDA (16561)
Job Trends (15006)
News (347123)
Policy (32765)
Tag
2027 BioCapital Elite (1)
2027 BioCapital Standard (1)
2027 BioMidwest Elite (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (2)
2027 Biotech Bay Standard (3)
2027 Biotech Beach Elite (1)
2027 Biotech Beach Standard (1)
2027 Genetown Elite (3)
2027 Genetown Standard (2)
2027 Pharm Country Elite (2)
2027 Pharm Country Standard (5)
Academia (2611)
Accelerated approval (55)
ADA (44)
Adcomms (29)
Allergies (193)
Alliances (49594)
ALS (226)
Alzheimer's disease (1845)
Antibody-drug conjugate (ADC) (526)
Approvals (17049)
Artificial intelligence (729)
ASCO (327)
Autoimmune disease (348)
Automation (63)
Bankruptcy (364)
Best Places to Work (11637)
BIO (69)
BIOSECURE Act (20)
Biosimilars (235)
Biotechnology (150)
Bladder cancer (204)
Brain cancer (75)
Breast cancer (804)
Cancer (6352)
Cardiovascular disease (506)
Career advice (1733)
Career pathing (45)
CAR-T (357)
CDC (58)
Celiac Disease (3)
Cell therapy (967)
Cervical cancer (56)
Clinical research (71618)
Collaboration (2213)
Commercialization (1)
Company closure (5)
Compensation (1527)
Complete response letters (85)
COVID-19 (2757)
CRISPR (117)
C-suite (1254)
Cystic fibrosis (158)
Data (8683)
Decentralized trials (3)
Denatured (29)
Depression (175)
Dermatology (99)
Diabetes (668)
Diagnostics (7040)
Digital health (65)
Diversity (13)
Diversity, equity & inclusion (45)
Drug discovery (364)
Drug pricing (202)
Drug shortages (31)
Duchenne muscular dystrophy (306)
Earnings (92243)
Editorial (68)
Employer branding (21)
Employer resources (155)
Events (120670)
Executive appointments (1135)
FDA (20614)
Fibrodysplasia Ossificans Progressiva (10)
Friedreich's ataxia (22)
Frontotemporal dementia (35)
Funding (1861)
Gene editing (247)
Generative AI (62)
Gene therapy (750)
GLP-1 (1094)
Government (4752)
Grass and pollen (6)
Guidances (421)
Healthcare (19149)
Hematology (193)
HIV (90)
Huntington's disease (62)
IgA nephropathy (113)
Immunology and inflammation (302)
Immuno-oncology (107)
Indications (222)
Infectious disease (3124)
Inflammatory bowel disease (222)
Inflation Reduction Act (14)
Influenza (143)
Intellectual property (320)
Interviews (321)
IPO (16681)
IRA (50)
Job creations (3651)
Job search strategy (1432)
JPM (58)
Kidney cancer (21)
Labor market (112)
Layoffs (578)
Leadership (42)
Legal (7957)
Liver cancer (103)
Longevity (35)
Lung cancer (836)
Lymphoma (480)
Machine learning (65)
Management (61)
Manufacturing (1161)
Marketing (4)
MASH (210)
Medical affairs (1)
Medical device (14005)
Medtech (14179)
Mergers & acquisitions (20285)
Metabolic disorders (1654)
mRNA (231)
Multiple sclerosis (200)
NASH (17)
Neurodegenerative disease (460)
Neuropsychiatric disorders (109)
Neuroscience (3484)
Neurotech (1)
NextGen: Class of 2026 (6525)
Non-profit (4539)
Now hiring (83)
Obesity (760)
Opinion (298)
Ovarian cancer (242)
Pain (267)
Pancreatic cancer (354)
Parkinson's disease (394)
Partnered (36)
Patents (644)
Patient recruitment (776)
Peanut (67)
People (59944)
Pharmaceutical (54)
Pharmacy benefit managers (33)
Phase 1 (22331)
Phase 2 (31554)
Phase 3 (23477)
Pipeline (9935)
Policy (331)
Postmarket research (2570)
Preclinical (9480)
Press Release (64)
Prostate cancer (336)
Psychedelics (57)
Radiopharmaceuticals (345)
Rare diseases (1189)
Real estate (5975)
Recruiting (71)
Regulatory (25875)
Reports (56)
Research institute (2425)
Resumes & cover letters (354)
Rett syndrome (46)
RNA editing (25)
RSV (90)
Schizophrenia (184)
Series A (317)
Series B (234)
Service/supplier (11)
Sickle cell disease (121)
Special edition (25)
Spinal muscular atrophy (169)
Sponsored (48)
Startups (3651)
State (2)
Stomach cancer (18)
Supply chain (134)
Tariffs (87)
The Weekly (66)
Vaccines (1155)
Venture capital (121)
Weight loss (484)
Women's health (138)
Worklife (21)
Date
Today (93)
Last 7 days (425)
Last 30 days (2105)
Last 365 days (30413)
2026 (16514)
2025 (30171)
2024 (35188)
2023 (40089)
2022 (51183)
2021 (55716)
2020 (54088)
2019 (46549)
2018 (35020)
2017 (32115)
2016 (31483)
2015 (37562)
2014 (31324)
2013 (26349)
2012 (28574)
2011 (29271)
2010 (27343)
Location
Africa (742)
Alabama (93)
Alaska (7)
Arizona (367)
Arkansas (14)
Asia (39974)
Australia (6559)
California (14056)
Canada (3991)
China (1501)
Colorado (599)
Connecticut (614)
Delaware (436)
Europe (86575)
Florida (2122)
Georgia (448)
Hawaii (3)
Idaho (63)
Illinois (1159)
India (100)
Indiana (633)
Iowa (25)
Japan (601)
Kansas (134)
Kentucky (51)
Louisiana (58)
Maine (76)
Maryland (1670)
Massachusetts (10073)
Michigan (377)
Minnesota (760)
Mississippi (6)
Missouri (149)
Montana (33)
Nebraska (30)
Nevada (150)
New Hampshire (84)
New Jersey (3675)
New Mexico (30)
New York (3697)
North Carolina (1771)
North Dakota (9)
Northern California (7106)
Ohio (420)
Oklahoma (23)
Oregon (41)
Pennsylvania (2792)
Puerto Rico (31)
Rhode Island (53)
South America (1113)
South Carolina (88)
South Dakota (2)
Southern California (5582)
Tennessee (231)
Texas (2258)
United States (49574)
Utah (419)
Vermont (2)
Virginia (344)
Washington D.C. (81)
Washington State (1117)
West Virginia (4)
Wisconsin (132)
Wyoming (2)
734,893 Results for "promedica crc inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Multitude Therapeutics Announces Encouraging Interim Phase I Results from Ongoing First-in-Human Study Evaluating its CDH17-directed Antibody-Drug-Conjugate, AMT-676, in patients with advanced CRC at the 2026 ESMO GI Cancer Congress
• AMT-676 is a potential first-in-class CDH17-directed ADC with a proprietary exatecan-based linker-payload design • AMT-676 demonstrated a favorable safety profile, similar to other TOP1-inhibitor based ADCs with reduced hematological toxicities • Promising antitumor activity was observed in heavily pretreated CRC patients
July 2, 2026
·
1 min read
Press Releases
Freenome’s SimpleScreen™ CRC Blood-Based Test Included in Updated ACS Colorectal Cancer Screening Guideline
May 27, 2026
·
3 min read
Press Releases
CRC CEO Tom Zoda, Ph.D., Chairs ASCP 2026 Panel on Preventable Failure Risk in CNS Clinical Trials
June 3, 2026
·
3 min read
Press Releases
Brenus Pharma Announces FDA Acceptance of IND Application for STC-1010 (BreAK-CRC001) in MSS Metastatic Colorectal Cancer (mCRC)
May 27, 2026
·
2 min read
Press Releases
Agenus and Noetik Present ASCO 2026 Data Linking AI Analysis of Routine Pretreatment Tumor Pathology Images to Response and Survival with BOT+BAL in MSS Metastatic CRC
May 22, 2026
·
8 min read
Press Releases
Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC)
April 2, 2026
·
5 min read
Press Releases
Cantargia Announces AACR 2026 Presentation of Study Design and Supportive Pre-Clinical Data for Investigator-Initiated Nadunolimab Study in MSS CRC
April 20, 2026
·
3 min read
Press Releases
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE574, a Potential First-In Class Dual Inhibitor of KAT6/7 to Target Multiple Solid Tumor Indications, including Breast, Prostate, CRC, and Lung Cancer
April 6, 2026
·
5 min read
Press Releases
Moleculin MIRACLE Trial Delivers 40% Preliminary Blinded CRc Rate (n=30)
February 18, 2026
·
10 min read
Press Releases
Freenome Delivers Improved Performance in Its Colorectal Cancer Blood Test with Sensitivity of 85% for CRC and 22% for Advanced Precancerous Lesions
January 6, 2026
·
3 min read
1 of 73,490
Next
